

# ESMO Advanced Course on Clinical Questions in Prostate Cancer

## Programme

**SINGAPORE**

**21-22 SEPTEMBER 2018**

Co-Chairs    Ravindran Kanesvaran, SG  
                  Stéphane Oudard, FR

# ESMO ADVANCED COURSE PROGRAMME CLINICAL QUESTIONS IN PROSTATE CANCER

Singapore  
21-22 September 2018

**CO-CHAIRS:** Ravindran Kanesvaran, Singapore  
Stéphane Oudard, France

**SPEAKERS:** Arun Azad, Australia  
Marniza Binti Saad, Malaysia  
Melvin Lee Kiang Chua, Singapore  
Ian Davis, Australia  
Jin Wei Kwek, Singapore  
Lui Shiong Lee, Singapore  
Puay Hoon Tan, Singapore

## LEARNING OBJECTIVES

- To understand essentials in the assessment and the value of multidisciplinary management of prostate cancer
- To learn about state-of-the-art advances in treatment of prostate cancer
- To learn the principles of management of advanced prostate cancer through direct exposure to real clinical scenarios

## ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 21 September 2018

---

- 09:00-09:20 **Welcome and course overview**  
Ravindran Kanesvaran, SG  
Stéphane Oudard, FR
- 09:20-10:55 **Session 1**  
**State-of-the-art in prostate cancer diagnostics**  
Updates in imaging  
Jin Wei Kwek, SG  
  
Advances in pathology  
Puay Hoon Tan, SG  
  
PSA screening  
Ravindran Kanesvaran, SG  
  
Germline mutations: The evolving role of cancer genetics in advanced prostate cancer  
Arun Azad, AU  
  
Discussion  
Faculty
- 10:55-11:15 *Coffee break*
- 11:15-12:45 **Session 2**  
**Localized prostate cancer**  
Role of surgery: Recent advances in surgical techniques  
Lui Shiong Lee, SG  
  
Role of radiotherapy: Recent advances in RT modalities  
Melvin Lee Kiang Chua, SG  
  
Active surveillance: Is it still a good option?  
Lui Shiong Lee, SG  
  
Discussion  
Faculty
- 12:45-13:45 *Lunch*
- 13:45-15:00 **Session 3**  
**Locally advanced and oligometastatic prostate cancer**  
Role of radiotherapy (including adjuvant RT for high risk disease): Current advances and where we stand now  
Melvin Lee Kiang Chua, SG  
  
Local complications and how to deal with it  
Lui Shiong Lee, SG  
  
Oligometastatic prostate cancer: Current data and controversies  
- Medical oncologist perspective. Stéphane Oudard, FR  
- Radiation oncologist perspective. Melvin Lee Kiang Chua, SG  
  
Discussion  
Faculty
- 15:00-16:15 **Session 4**  
**Metastatic prostate cancer**  
Metastatic hormone sensitive prostate cancer: State-of-the-art management in 2018  
Arun Azad, AU

M0 Castrate Resistant Prostate Cancer (CRPC): Is metastasis-free survival (MFS) a practice changing endpoint?

Ian Davis, AU

Metastatic CRPC: State-of-the-art management in 2018

Stéphane Oudard, FR

Discussion

Faculty

16:15-16:35

*Coffee break*

16:35-17:30

**Session 5**

**Special sessions**

Resource stratified practice of prostate cancer management in Asia

Marniza Binti Saad, MY

ESMO Magnitude of Clinical Benefit Scale

Ravindran Kanesvaran, SG

Discussion and summary

Ravindran Kanesvaran, SG

Stéphane Oudard, FR

19:00

*Networking dinner*

## Saturday, 22 September 2018

---

09:00-12:30

**Workshop sessions**

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotation basis)

15' Introduction based on clinical cases presented by speakers

40' Discussion

5' Break

Workshop 1

**Localized prostate cancer**

Melvin Lee Kiang Chua, SG

Lui Shiong Lee, SG

Workshop 2

**Metastatic prostate cancer**

Arun Azad, AU

Stéphane Oudard, FR

Workshop 3

**Bone modulating agents in the treatment of metastatic prostate cancer**

Ian Davis, AU

Marniza Binti Saad, MY

11:00-11:30

*Coffee break*

12:30-13:00

**Feedback on the workshop from each group**

13:00-13:15

**Synthesis and wrap-up**

Ravindran Kanesvaran, SG

Stéphane Oudard, FR

13:15-14:15

*Lunch*